In summary, survival of primordial oocytes in Chek2−/− ex vivo–treated ovaries demonstrates that CHEK2 is directly responsible for coordinating elimination of PMFs after treatment with four different chemotherapy drugs and that CHEK2 inhibition would likely be sufficient to prevent loss of PMF reserve in cancer patients treated with these drugs. This evidence concerns the gene CHEK2 and cancer.